

Science Capital Drugs, Diagnostics & Delivery







Birmingham Science City



Cancer Treatment: Diagnosis & Clinical Trials

CANCER RESEARCH UK



Philip Johnson Professor of Oncology & Director of the CR UK Clinical Trials Unit School of Cancer Studies University of Birmingham

What Is Cancer?



Naming of Cancers

Cancers are named after the *primary* site i.e. the organ in which the cancer starts

The organ to which the cancer spreads is known as the *secondary* site (a 'metastasis')



Examples Of Cancer Metastasis



Primary

Secondary (metastases)





Cancer – The Fundamental Problem

We are very good at treating/curing cancer when it is small/early and has not spread

We are much less adept at treating cancer once it has spread – 'metastasised' - & is at an advanced stage

What's in the cancer treatment tool box?

Tools for Cancer Treatment

The Aim

For primary disease

- Surgery
- Radiotherapy

For metastatic disease

Drugs (Chemotherapy)

When cure/survival extension

is not an option

- Palliation

Cure

Cure or prolongation of survival

Control of Symptoms

What other cancer control strategies do we have and how are drugs used?

Other Strategies For Cancer Control & The Role Of Drugs

Prevent it starting in the first place!



What kind of drugs do we have to implement this strategy?

Drug Treatment of Advanced Cancer

20th Century Approach To Treatment Cytotoxic drugs **21**st Century Approach to Treatment Targeted drugs

Not rationally designed Often discovered by serendipity or 'fishing' Non-specific - hit rapidly dividing cells Renowned for nasty side effects Cause intellectual indigestion

BUT

Cheap

Can cure some cancers, even without knowing how they work

Rationally designed **Target** relevant biochemical pathways Intellectually satisfying Less side-effects are expected

BUT

Their modest benefit for great expense poses a 'NICE' problem

Cisplatin - The Most Widely Used Cytotoxic Drug Serendipity & Inspiration & Perspiration

Researchers found that an electric current inhibited growth of bacterial cell division

Would it inhibit growth in mammalian cells – Yes!, But why?..



Electrolysis products from the platinum electrodes! And that it could cure cancers in animal models

> Barnett Rosenberg, Loretta van Camp, Thomas Krigas "Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode" Nature 1965, Vol 205, page 698

Imatinib & Chronic Myeloid Leukaemia The Appliance Of Science



Normal Bcr-Abl Signaling

Once activated by phosphorylation, the signaling that results in the leukemia is initiated



Savage and Antman. *N Engl J Med.* 2002;346:683 Scheijen and Griffin. *Oncogene.* 2002;21:3314.

Imatinib, In Theory And In Practice, Treats The Leukaemia

- Imatinib occupies the ATP binding pocket of the Abl kinase domain
- prevents substrate phosphorylation and signaling
- And the treatment of Chronic Leukaemia is revolutionised

But most cancers aren't so simple, and most targeted drugs aren't so effective...!



More Typical Examples Of Targeted Drugs Both subject of a negative assessment by NICE, on grounds of limited cost-effectiveness

Avastin (Bevacizumab) for advanced colon cancer

When added to conventional cytotoxic therapy improved survival from 15 to 20 months

Cost- around £25,000 per patient

Nexavar (Sorafenib) for Liver cancer

First agent to show benefit in advanced disease.... from about 8 to 11 months

Cost – around £25, 000

Avastin (Bevacizumab) For Colon Cancer



Cancers need their own blood supply Inhibition of blood vessels is a major therapeutic area Avastin was designed to do this & Increases survival from 15 to 20 months



Trajectory Of Cancer Treatment Progress is Incremental

Effectiveness



Baseline No treatment

Trajectory Of Cancer Treatment Progress In Advanced Colorectal Cancer

Effectiveness



Avastin For Colon Cancer

Stabilises chaotic cancer related blood vessels

improves access of conventional cytotoxic agents

The Clinical Trial Process

Phase I

Test in small group of patients -safety -side effects -proper dosage -how to best give drug

 now to best give drug (pill or injection)



Phase II

Test in small group of patients -effectiveness of drug -safety



Phase III

Test in large group of patients -patients randomly assigned to group receiving new drug or group receiving standard treatment



Adopted for general use if trials are successful Does it do 'what is says on the tin' Usually, shrink the tumour

Is it safe?

By shrinking the tumour does it make people live longer, than current best therapy

The Sorafenib pathway



No, it did not shrink tumours

\$100M

Yes, people taking the drug live longer

So we don't know the best signal to move, at a cost of millions of pounds, to phase III

Trajectory Of Cancer Treatment Progress is Incremental

Effectiveness



Time

Baseline No treatment

It's Not Just About Making A Drug!

Identifying dysregulated pathways &
Developing, in the lab, a potential drug

Drug development

Developing methods to assess whether it works, & can be licensed at a proportionate cost

Spending More – Getting Less Looking Into The Crocodile's Mouth



CMR international

For Any Given Cancer Type.... The Medical Options

Prevent it starting in the first place!



And Finally An Historical Note.....

μ7: E. 1.7

Translation: "Superior doctors prevent the disease. Mediocre doctors treat the disease before evident. Inferior doctors treat the full blown disease." Huang Dee: Nai-Ching (2600 BC, 1st Chinese Medical Text).